The effectiveness of carbamazepine in unipolar depression: A double-blind, randomized, placebo-controlled study

Zhang, Zhang-Jin; Tan, Qingrong; Tong, Yao; Li, Qiang; Kang, Wan-Hu; Zhen, Xuechu; Post, Robert M.

doi:10.1016/j.jad.2007.11.004

Cited by 25 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite this observation, prior psychiatric disorders and those measured at the 6-M interval acquired greater relevance in the multiple regression analyses. Other variables were found to have a protective role against depression, such as the administration of carbamazepine, which is consistent with its stabilizing properties [34], and with the administration of levetiracetam, despite the adverse behavioral effects reported with its use [35,36]. Also, the absence of psychiatric treatment was a protective factor for anxiety and taking pregabalin and gabapentin [35] could worsen depression.…”

Section: Discussionmentioning

confidence: 69%

Psychiatric Symptoms in Refractory Epilepsy During the First Year After Surgery

Ramos-Perdigues¹,

Baillès

Mané

et al. 2018

Neurotherapeutics

View full text Add to dashboard Cite

Psychiatric morbidity in drug-resistant epilepsy is frequent. Surgery is the best therapeutic alternative for treating seizures, but the current evidence concerning the effects of surgery on psychiatric disorders (PDs) is inconclusive. We aim to clarify surgery's role in long-term PDs. Using a prospective controlled study, we analyzed the psychopathologic outcomes of patients with drug-resistant epilepsy, comparing those who underwent surgery to those who did not due to not being suitable. Surgical candidates were paired (n = 84) with the immediately following nonsurgical candidates (n = 68). Both groups continued their usual medical treatment. We studied psychiatric changes for each group and analyzed de novo and remission cases. The assessments were made during the presurgical evaluation, and at 6 months (6-M) and 12 months (12-M) after surgery. Finally, we determined associated factors for postsurgical PDs. At 12 months, using the Hospital Anxiety and Depression Scale (HADS), anxiety improved in both groups (p = 0.000), while depression improved only in the surgical group (p = 0.016). Moreover, all symptom dimensions on the Symptom Checklist-90-R (SCL-90), as well as severity, distress, and total symptoms, decreased only in the surgical group. These ameliorations reached not only statistical significance but also clinical significance for depression (HADS) (p = 0.014) and the interictal dysphoric disorder (p = 0.013). The main predictors for PDs after surgery were as follows: the presurgical and 6-month psychiatric symptoms, the absence of surgery, seizure outcomes, and some antiepileptic and psychiatric drugs. This study provides evidence that surgery for epilepsy could have a role in improving some symptoms of psychiatric disorders 12-M after the surgery.

show abstract

Section: Discussionmentioning

confidence: 69%

Psychiatric Symptoms in Refractory Epilepsy During the First Year After Surgery

Ramos-Perdigues¹,

Baillès

Mané

et al. 2018

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…Indeed, the changes in ADHD symptoms recorded here were equivalent or larger than those reported from conventional treatments like methylphenidate (Medori et al, 2008) or atemoxetine [Reimherr et al, 2005] in adult samples. Furthermore, the changes on the MADRS [10 (83.3%) of the 12 participants who entered the trial with clinically elevated symptoms of depression showed a 50% reduction in symptoms post 8-weeks] are again equivalent or better than published studies using antidepressants [e.g., carbamazapine (Zhang et al, 2008) and venlafaxine/fluoxetine (Costa e Silva, 1998;Nemeroff & Thase, 2007) and cognitivebehavioral and interpersonal therapy (Luty et al, 2007)]. Furthermore, this study also replicates other international studies showing the benefit of EMP+ in the treatment of mental illness.…”

Section: Discussionmentioning

confidence: 84%

Effect of Micronutrients on Behavior and Mood in Adults With ADHD: Evidence From an 8-Week Open Label Trial With Natural Extension

Rucklidge

Taylor

Whitehead³

2010

J Atten Disord

View full text Add to dashboard Cite

show abstract

“…We found inadequate data to evaluate the efficacy of lithium compared either to placebo or antidepressants in acute, unipolar, major depressive episodes (Table 1), although another mood-stabilizing agent, carbamazepine, may be effective (Zhang et al 2008). However, lithium was effective as an adjunctive treatment to augment responses to antidepressants for acute major depressive episodes, including cases of TRD, with an overall OR of 2.34, p <0.0001), though only 4/12 individual trials individually found significant superiority for lithium (Table 2).…”

Section: Discussionmentioning

confidence: 99%

Lithium treatment for unipolar major depressive disorder: Systematic review

et al. 2019

View full text Add to dashboard Cite

Background: The potential value of lithium treatment in particular aspects of unipolar major depressive disorder remains uncertain. Methods: With reports of controlled trials identified by systematic searching of Medline, Cochrane Library, and PsycINFO literature databases, we summarized responses with lithium and controls followed by selective random-effects meta-analyses. Results: We identified 36 reports with 39 randomized controlled trials: six for monotherapy and 12 for adding lithium to antidepressants for acute major depression, and 21 for long-term treatment. Data for monotherapy of acute depression were few and inconclusive. As an adjunct to antidepressants, lithium was much more effective than placebo (p<0.0001). For long-term maintenance treatment, lithium was more effective than placebo in monotherapy (p=0.011) and to supplement antidepressants (p=0.038), and indistinguishable from antidepressant monotherapy. Conclusions: The findings indicate efficacy of lithium as a treatment for some aspects of major depressive disorder, especially as an add-on to antidepressants and for long-term prophylaxis. It remains uncertain whether some benefits of lithium treatment occur with many major depressive disorder patients, or if efficacy is particular to a subgroup with bipolar disorder-like characteristics or mixed-features.

show abstract

The effectiveness of carbamazepine in unipolar depression: A double-blind, randomized, placebo-controlled study

Cited by 25 publications

References 33 publications

Psychiatric Symptoms in Refractory Epilepsy During the First Year After Surgery

Psychiatric Symptoms in Refractory Epilepsy During the First Year After Surgery

Effect of Micronutrients on Behavior and Mood in Adults With ADHD: Evidence From an 8-Week Open Label Trial With Natural Extension

Lithium treatment for unipolar major depressive disorder: Systematic review

Contact Info

Product

Resources

About